OUR COVID-19 RESPONSE

iStock_37438014_XXXLARGE-outlined_LM.png pink_scrubs.png hp-people-3.png man-in-sweater_90824869_v1MAG.png Dr-Glasses.png iStock_86712797_XXXLARGE-outline_LM.png blue_shirt_masthead_man_v1_MAG.png NKT-hp-people-Michelle_v1_LM.png iStock_68713947_XXLARGE-outiline_LM.png NKT-hp-people-Phi_v1_LM.png NKT-hp-people-Mekhala_v1_LM.png hp-people-3.png iStock_87627749_XXXLARGE-outline_LM.png

Events

MAR 03

Cowen 40th Annual Health Care Conference
Boston, MA
9:20 a.m. ET/6:20 a.m. PT

Presentation - 9:20 a.m. ET/6:20 a.m. PT
Listen to Webcast
10:00 a.m. ET/7:00 a.m. PT
Listen to Webcast
Presentation Slides

FEB 27

Q4 & YE 2019 Financial Results Conference Call
San Francisco, CA
5:00 p.m. ET/2:00 p.m. PT

(877) 881-2183 (U.S.); (970) 315-0453 (int’l)
Conference ID: 2507828
Webcast Link

JAN 13

38th Annual J.P. Morgan Healthcare Conference
San Francisco, CA
2:30 pm PT

Presentation – 2:30 p.m. PT
Listen to Webcast 

Q&A – 3:00 p.m. PT

Listen to Webcast 

Presentation Slides

Leadership Spotlight

Dr. Jonathan Zalevsky, Chief Research & Development Officer discusses bempegaldesleukin (NKTR-214)

Watch

#

Latest News

OUR PIPELINE

We are focused on using new chemistry approaches to make better medicines to treat cancer and auto-immune disease.

Bempegaldesleukin

IMMUNO-ONCOLOGY

Phase 3

  • 9

    9 million patients benefit from our medicines

    9
    9
    9

  • 12

    12 approved products around the world

    12
    12
    12

  • 10

    10 new medicines in development pipeline

    10
    10
    10


Cutting-edge facilities




Dynamic teams




Impactful work


OUR Culture

We are supported by a dynamic team, rich in scientific, business and medical expertise, across three locations.

Read more